Melur Ramakrishnaiah

Array ( [id] => 18817507 [patent_doc_number] => 20230391847 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-07 [patent_title] => PROCESSES FOR MAKING AND USING A CELLULAR FIBRONECTIN COMPOSITION [patent_app_type] => utility [patent_app_number] => 18/448294 [patent_app_country] => US [patent_app_date] => 2023-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26674 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18448294 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18808653 [patent_doc_number] => 20230382987 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-30 [patent_title] => MONOCLONAL ANTIBODIES TO GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15), AND USESTHEREOF FOR TREATING CANCER CACHEXIA AND CANCER [patent_app_type] => utility [patent_app_number] => 18/364173 [patent_app_country] => US [patent_app_date] => 2023-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25782 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -55 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18364173 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18754013 [patent_doc_number] => 20230357377 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => METHODS OF ALTERING BONE GROWTH BY ADMINISTRATION OF SOST OR WISE ANTAGONIST OR AGONIST [patent_app_type] => utility [patent_app_number] => 18/339147 [patent_app_country] => US [patent_app_date] => 2023-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9400 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18339147 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18922982 [patent_doc_number] => 20240025986 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => THERAPY FOR GLAUCOMA AND OPTIC NEUROPATHY BY TARGETING COLONY STIMULATING FACTORS [patent_app_type] => utility [patent_app_number] => 18/318336 [patent_app_country] => US [patent_app_date] => 2023-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14606 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18318336 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18598422 [patent_doc_number] => 20230273221 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => METHOD RELATING TO MYOSTATIN PATHWAY INHIBITION [patent_app_type] => utility [patent_app_number] => 18/312879 [patent_app_country] => US [patent_app_date] => 2023-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10163 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18312879 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18970452 [patent_doc_number] => 20240050544 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-15 [patent_title] => COMBINATION THERAPY WITH SEMAPHORIN-4D BLOCKADE (SEMA4D) AND DC1 THERAPY [patent_app_type] => utility [patent_app_number] => 18/307920 [patent_app_country] => US [patent_app_date] => 2023-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18020 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18307920 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18770867 [patent_doc_number] => 20230365669 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => USE OF ANTI-SCLEROSTIN ANTIBODIES IN THE TREATMENT OF OSTEOGENESIS IMPERFECTA [patent_app_type] => utility [patent_app_number] => 18/297280 [patent_app_country] => US [patent_app_date] => 2023-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16254 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18297280 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18748385 [patent_doc_number] => 11807681 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-07 [patent_title] => Methods of altering bone growth by administration of Sost or Wise antagonist or agonist [patent_app_type] => utility [patent_app_number] => 18/123569 [patent_app_country] => US [patent_app_date] => 2023-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9424 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18123569 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18581610 [patent_doc_number] => 20230263862 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => FORMATION OF BONE [patent_app_type] => utility [patent_app_number] => 18/183676 [patent_app_country] => US [patent_app_date] => 2023-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10140 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18183676 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18860243 [patent_doc_number] => 20230414677 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => ALLOGRAFT TOLERANCE WITHOUT THE NEED FOR SYSTEMIC IMMUNE SUPPRESSION [patent_app_type] => utility [patent_app_number] => 18/175409 [patent_app_country] => US [patent_app_date] => 2023-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63726 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18175409 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18647858 [patent_doc_number] => 20230293634 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-21 [patent_title] => ACTIVIN-ACTRII ANTAGONISTS AND USES FOR TREATING BONE AND OTHER DISORDERS [patent_app_type] => utility [patent_app_number] => 18/156015 [patent_app_country] => US [patent_app_date] => 2023-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37282 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18156015 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18955158 [patent_doc_number] => 20240043485 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => THERAPEUTIC USE OF BONE MORPHOGENETIC PROTEINS [patent_app_type] => utility [patent_app_number] => 18/149403 [patent_app_country] => US [patent_app_date] => 2023-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9139 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18149403 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18675113 [patent_doc_number] => 20230312696 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => Compositions and Methods of Use for Treating Metabolic Disorders [patent_app_type] => utility [patent_app_number] => 17/982390 [patent_app_country] => US [patent_app_date] => 2022-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29714 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17982390 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18657734 [patent_doc_number] => 20230303686 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-28 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING FIBROTIC DISEASES [patent_app_type] => utility [patent_app_number] => 17/971520 [patent_app_country] => US [patent_app_date] => 2022-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46729 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17971520 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18522995 [patent_doc_number] => 20230233648 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION [patent_app_type] => utility [patent_app_number] => 17/960911 [patent_app_country] => US [patent_app_date] => 2022-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68689 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17960911 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18649475 [patent_doc_number] => 20230295288 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-21 [patent_title] => ANTIBODY VARIANTS [patent_app_type] => utility [patent_app_number] => 17/948814 [patent_app_country] => US [patent_app_date] => 2022-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14325 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17948814 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18649472 [patent_doc_number] => 20230295285 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-21 [patent_title] => METHODS OF REVERSING CACHEXIA AND PROLONGING SURVIVAL COMPRISING ADMINISTERING A GDF15 MODULATOR AND AN ANTI-CANCER AGENT [patent_app_type] => utility [patent_app_number] => 17/939634 [patent_app_country] => US [patent_app_date] => 2022-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10078 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17939634 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18553259 [patent_doc_number] => 20230251271 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-10 [patent_title] => METABOLIC BIOMARKERS FOR PREDICTING RESPONSIVENESS TO FGF-18 COMPOUND [patent_app_type] => utility [patent_app_number] => 17/930389 [patent_app_country] => US [patent_app_date] => 2022-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11223 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930389 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18568323 [patent_doc_number] => 20230258659 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-17 [patent_title] => INFLAMMATORY BIOMARKERS FOR PREDICTING RESPONSIVENESS TO FGF-18 COMPOUND [patent_app_type] => utility [patent_app_number] => 17/929261 [patent_app_country] => US [patent_app_date] => 2022-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12068 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17929261 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18036233 [patent_doc_number] => 20220380448 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-01 [patent_title] => ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/816484 [patent_app_country] => US [patent_app_date] => 2022-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54943 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17816484 [rel_patent_id] =>[rel_patent_doc_number] =>)